Loading clinical trials...
Loading clinical trials...
Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone
Conditions
Interventions
GLPG0634
Placebo
Locations
142
United States
Rheumatology Associates of North Alabama, PC
Huntsville, Alabama, United States
Artho Care, Arthritis Care & Research P.C.
Gilbert, Arizona, United States
Arizona Arthritis & Rheumatology Research PLLC
Phoenix, Arizona, United States
C.V. Mehta MD Medical Corporation
Hemet, California, United States
Center for Innovative TherapyDivision of Rheumatology, UCSD
La Jolla, California, United States
Desert Medical Advances
Palm Desert, California, United States
Start Date
July 17, 2013
Primary Completion Date
February 18, 2015
Completion Date
May 14, 2015
Last Updated
November 17, 2020
NCT07536529
NCT06329401
NCT07048197
NCT07484243
NCT06647069
NCT06841562
Lead Sponsor
Galapagos NV
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions